Teva Pharmaceutical Industries (NYSE:TEVA) Issues FY 2026 Earnings Guidance

Teva Pharmaceutical Industries (NYSE:TEVA) issued an update on its FY 2026 earnings guidance on Wednesday morning. The company provided earnings per share (EPS) guidance of 1.910-2.110 for the period, compared to the consensus estimate of 2.170. The company issued revenue guidance of $16.5 billion-$16.9 billion, compared to the consensus revenue estimate of $16.7 billion.

Wall Street Analyst Weigh In

Several analysts recently weighed in on the company. Bank of America lifted their price objective on Teva Pharmaceutical Industries from $38.00 to $42.00 and gave the company a “buy” rating in a report on Thursday, April 9th. JPMorgan Chase & Co. raised their target price on shares of Teva Pharmaceutical Industries from $35.00 to $40.00 and gave the company an “overweight” rating in a research report on Thursday, April 30th. Weiss Ratings restated a “sell (d-)” rating on shares of Teva Pharmaceutical Industries in a report on Friday, July 17th. Barclays upped their price target on shares of Teva Pharmaceutical Industries from $38.00 to $40.00 and gave the stock an “overweight” rating in a research report on Wednesday, May 6th. Finally, UBS Group increased their price objective on shares of Teva Pharmaceutical Industries from $36.00 to $42.00 and gave the company a “buy” rating in a research note on Thursday, April 30th. Nine investment analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $42.00.

Teva Pharmaceutical Industries Stock Up 1.1%

Shares of NYSE TEVA traded up $0.39 during mid-day trading on Thursday, reaching $35.10. 3,765,243 shares of the company were exchanged, compared to its average volume of 7,288,052. Teva Pharmaceutical Industries has a 1 year low of $14.99 and a 1 year high of $37.35. The firm has a 50-day moving average of $33.19 and a 200 day moving average of $32.69. The stock has a market cap of $40.36 billion, a price-to-earnings ratio of 26.44, a P/E/G ratio of 3.35 and a beta of 0.86. The company has a quick ratio of 0.78, a current ratio of 1.01 and a debt-to-equity ratio of 1.70.

Teva Pharmaceutical Industries (NYSE:TEVA) last announced its earnings results on Tuesday, June 30th. The company reported $0.02 EPS for the quarter. The business had revenue of $4.14 billion during the quarter. Teva Pharmaceutical Industries had a net margin of 9.01% and a return on equity of 43.53%. On average, research analysts expect that Teva Pharmaceutical Industries will post 1.98 earnings per share for the current year.

Insiders Place Their Bets

In other news, EVP Richard Daniell sold 30,000 shares of the business’s stock in a transaction dated Tuesday, May 5th. The stock was sold at an average price of $35.40, for a total transaction of $1,062,000.00. Following the sale, the executive vice president owned 55,755 shares in the company, valued at approximately $1,973,727. The trade was a 34.98% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CAO Amir Weiss sold 10,679 shares of the company’s stock in a transaction on Wednesday, May 6th. The shares were sold at an average price of $36.00, for a total value of $384,444.00. Following the completion of the transaction, the chief accounting officer directly owned 20,016 shares in the company, valued at approximately $720,576. The trade was a 34.79% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. In the last ninety days, insiders have sold 444,673 shares of company stock valued at $15,582,369. 0.54% of the stock is owned by corporate insiders.

Key Teva Pharmaceutical Industries News

Here are the key news stories impacting Teva Pharmaceutical Industries this week:

• Positive Sentiment: Teva raised its 2026 revenue guidance to $16.5 billion–$16.9 billion, with the midpoint $75 million above its prior forecast. The increase reflects continued momentum in its innovative medicines portfolio. Teva outlines higher 2026 revenue midpoint
• Positive Sentiment: Growth in newer branded products is strengthening Teva’s long-term investment case. Innovative brands grew 43% year over year in local-currency terms to more than $1 billion in quarterly revenue. AUSTEDO, UZEDY and AJOVY all received higher 2026 targets; UZEDY sales reached a record $77 million, up 43%, prompting an increased outlook of $270 million–$290 million. Teva delivers strong Q2 results
• Positive Sentiment: Piper Sandler raised its price target from $42 to $44 and maintained an “overweight” rating, implying substantial potential appreciation from recent trading levels. Unusually heavy call-option activity and positive analyst attention may also be supporting sentiment. Piper Sandler forecasts strong price appreciation
• Neutral Sentiment: Second-quarter revenue was approximately $4.14 billion, ahead of expectations near $4.02 billion, but declined roughly 1% year over year as generics sales weakened. Management’s branded-drug pivot is improving the portfolio mix, though investors are weighing whether that growth can offset pressure on the legacy generics business. Teva lifts sales view
• Negative Sentiment: Teva reported quarterly EPS of $0.02, below the $0.08 consensus and sharply below $0.66 a year earlier. Net income swung to a $576 million loss from $282 million of profit, partly because of impairment charges and acquisition-related costs. Full-year EPS guidance of $1.91–$2.11 is also below the $2.17 analyst consensus, creating a significant risk despite the improved revenue outlook.

Institutional Investors Weigh In On Teva Pharmaceutical Industries

Hedge funds have recently modified their holdings of the business. Aster Capital Management DIFC Ltd purchased a new stake in Teva Pharmaceutical Industries during the 4th quarter valued at about $25,000. Caitong International Asset Management Co. Ltd boosted its holdings in shares of Teva Pharmaceutical Industries by 567.0% during the 4th quarter. Caitong International Asset Management Co. Ltd now owns 1,334 shares of the company’s stock worth $42,000 after purchasing an additional 1,134 shares during the last quarter. Global Retirement Partners LLC boosted its holdings in shares of Teva Pharmaceutical Industries by 27.3% during the 4th quarter. Global Retirement Partners LLC now owns 1,360 shares of the company’s stock worth $42,000 after purchasing an additional 292 shares during the last quarter. Advocate Investing Services LLC purchased a new stake in shares of Teva Pharmaceutical Industries in the fourth quarter valued at approximately $53,000. Finally, DV Equities LLC purchased a new stake in shares of Teva Pharmaceutical Industries in the fourth quarter valued at approximately $69,000. 54.05% of the stock is currently owned by institutional investors and hedge funds.

About Teva Pharmaceutical Industries

Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) is an Israeli multinational pharmaceutical company and one of the world’s largest manufacturers of generic medicines. The company’s core activities include the development, production and marketing of generic pharmaceuticals alongside a portfolio of specialty branded medicines. Teva supplies finished dosage forms and active pharmaceutical ingredients (APIs) to markets around the globe and operates manufacturing and research facilities in multiple countries.

Teva’s product range covers oral solids, injectables, inhalation products and other dosage forms across therapeutic areas such as central nervous system disorders, respiratory, oncology, pain and infectious disease.